Protagenic Therapeutics, Inc.\new annual total assets
2014
2015
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Protagenic Therapeutics, Inc.\new Total Assets Growth & History (PTIX)
Protagenic Therapeutics, Inc.\new's total assets was $3.7M for fiscal 2026.
View full Protagenic Therapeutics, Inc.\new company overviewProtagenic Therapeutics, Inc.\new annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $3.7M | $3.6M | +3997.26% |
| 2025 | 2025-03-31 | $89,093 | — | — |
| 2024 | 2024-12-31 | $2.0M | −$2.4M | −54.76% |
| 2023 | 2023-12-31 | $4.3M | −$3.7M | −46.21% |
| 2022 | 2022-12-31 | $8.0M | −$3.0M | −27.33% |
| 2021 | 2021-12-31 | $11.1M | $10.2M | +1157.89% |
| 2020 | 2020-12-31 | $879,247 | $36,974 | +4.39% |
| 2019 | 2019-12-31 | $842,273 | $145,389 | +20.86% |
| 2018 | 2018-12-31 | $696,884 | −$1.1M | −60.87% |
| 2017 | 2017-12-31 | $1.8M | −$1.4M | −43.67% |
| 2016 | 2016-12-31 | $3.2M | $3.2M | +28278.32% |
| 2015 · Dec 31 | 2015-12-31 | $11,142 | — | — |
| 2015 · Jun 30 | 2015-06-30 | $133,000 | −$113,000 | −45.93% |
| 2014 | 2014-06-30 | $246,000 | — | — |
Protagenic Therapeutics, Inc.\new quarterly total assets
As of Jun 30, 2011
As of Sep 30, 2011
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $2.8M | −$3.7M | −56.91% |
| Q4 2026 | 2026-03-31 | $3.7M | $3.6M | +3997.26% |
| Q3 2026 | 2025-12-31 | $4.4M | $2.5M | +126.55% |
| Q2 2026 | 2025-09-30 | $5.0M | $3.5M | +231.68% |
| Q1 2026 | 2025-06-30 | $6.5M | $5.0M | +342.25% |
| Q4 2025 | 2025-03-31 | $89,093 | −$2.5M | −96.54% |
| Q4 2024 | 2024-12-31 | $2.0M | −$2.4M | −54.76% |
| Q3 2024 | 2024-09-30 | $1.5M | −$3.9M | −72.24% |
| Q2 2024 | 2024-06-30 | $1.5M | −$5.5M | −78.80% |
| Q1 2024 | 2024-03-31 | $2.6M | −$5.1M | −66.36% |
| Q4 2023 | 2023-12-31 | $4.3M | −$3.7M | −46.21% |
| Q3 2023 | 2023-09-30 | $5.4M | −$2.8M | −34.18% |
| Q2 2023 | 2023-06-30 | $6.9M | −$2.1M | −23.24% |
| Q1 2023 | 2023-03-31 | $7.7M | −$2.1M | −21.76% |
| Q4 2022 | 2022-12-31 | $8.0M | −$3.0M | −27.33% |
| Q3 2022 | 2022-09-30 | $8.3M | −$3.4M | −29.19% |
| Q2 2022 | 2022-06-30 | $9.0M | −$3.0M | −25.27% |
| Q1 2022 | 2022-03-31 | $9.8M | $9.6M | +4895.51% |
| Q4 2021 | 2021-12-31 | $11.1M | $10.2M | +1157.89% |
| Q3 2021 | 2021-09-30 | $11.7M | $10.7M | +1063.37% |
| Q2 2021 | 2021-06-30 | $12.1M | $10.9M | +915.41% |
| Q1 2021 | 2021-03-31 | $196,142 | −$589,706 | −75.04% |
| Q4 2020 | 2020-12-31 | $879,247 | $36,974 | +4.39% |
| Q3 2020 | 2020-09-30 | $1.0M | $714,723 | +248.78% |
| Q2 2020 | 2020-06-30 | $1.2M | $838,143 | +239.63% |
| Q1 2020 | 2020-03-31 | $785,848 | $321,067 | +69.08% |
| Q4 2019 | 2019-12-31 | $842,273 | $145,389 | +20.86% |
| Q3 2019 | 2019-09-30 | $287,291 | −$703,160 | −70.99% |
| Q2 2019 | 2019-06-30 | $349,768 | −$742,661 | −67.98% |
| Q1 2019 | 2019-03-31 | $464,781 | −$1.0M | −68.36% |
| Q4 2018 | 2018-12-31 | $696,884 | −$1.1M | −60.87% |
| Q3 2018 | 2018-09-30 | $990,451 | −$1.2M | −55.38% |
| Q2 2018 | 2018-06-30 | $1.1M | −$1.4M | −55.50% |
| Q1 2018 | 2018-03-31 | $1.5M | −$1.3M | −46.95% |
| Q4 2017 | 2017-12-31 | $1.8M | −$1.4M | −43.67% |
| Q3 2017 | 2017-09-30 | $2.2M | −$1.4M | −38.12% |
| Q2 2017 | 2017-06-30 | $2.5M | −$1.3M | −35.22% |
| Q1 2017 | 2017-03-31 | $2.8M | −$982,983 | −26.20% |
| Q4 2016 | 2016-12-31 | $3.2M | $3.2M | +28278.32% |
| Q3 2016 | 2016-09-30 | $3.6M | $3.5M | +5878.19% |
| Q2 2016 | 2016-06-30 | $3.8M | $3.7M | +2749.34% |
| Q1 2016 · Mar 31 | 2016-03-31 | $3.8M | $3.6M | +2435.38% |
| Q4 2015 · Dec 31 | 2015-12-31 | $11,142 | −$249,858 | −95.73% |
| Q1 2016 · Sep 30 | 2015-09-30 | $60,000 | −$186,000 | −75.61% |
| Q4 2015 · Jun 30 | 2015-06-30 | $133,000 | −$113,000 | −45.93% |
| Q3 2015 | 2015-03-31 | $148,000 | — | — |
| Q2 2015 | 2014-12-31 | $261,000 | — | — |
| Q1 2015 | 2014-09-30 | $246,000 | — | — |
| Q4 2014 | 2014-06-30 | $246,000 | — | — |
| As of Sep 30, 2011 | 2011-09-30 | $14.1M | — | — |
| As of Jun 30, 2011 | 2011-06-30 | $15.0M | — | — |
Protagenic Therapeutics, Inc.\new total assets trends
Between the periods ended 2014-06-30 and 2026-03-31, Protagenic Therapeutics, Inc.\new's total assets increased from $246,000 to $3.7M, a change of $3.4M. The latest reported quarter, Q1 2027, shows $2.8M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagenic Therapeutics, Inc.\new source filings ↗